GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Editas Medicine Inc (NAS:EDIT) » Definitions » Cyclically Adjusted PB Ratio

EDIT (Editas Medicine) Cyclically Adjusted PB Ratio : 0.47 (As of Jul. 18, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Editas Medicine Cyclically Adjusted PB Ratio?

As of today (2025-07-18), Editas Medicine's current share price is $2.76. Editas Medicine's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was $5.85. Editas Medicine's Cyclically Adjusted PB Ratio for today is 0.47.

The historical rank and industry rank for Editas Medicine's Cyclically Adjusted PB Ratio or its related term are showing as below:

EDIT' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.18   Med: 0.37   Max: 0.98
Current: 0.47

During the past years, Editas Medicine's highest Cyclically Adjusted PB Ratio was 0.98. The lowest was 0.18. And the median was 0.37.

EDIT's Cyclically Adjusted PB Ratio is ranked better than
74.19% of 678 companies
in the Biotechnology industry
Industry Median: 1.66 vs EDIT: 0.47

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Editas Medicine's adjusted book value per share data for the three months ended in Mar. 2025 was $0.746. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $5.85 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Editas Medicine Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Editas Medicine's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Editas Medicine Cyclically Adjusted PB Ratio Chart

Editas Medicine Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 0.22

Editas Medicine Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.81 0.58 0.22 0.20

Competitive Comparison of Editas Medicine's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Editas Medicine's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Editas Medicine's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Editas Medicine's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Editas Medicine's Cyclically Adjusted PB Ratio falls into.


;
;

Editas Medicine Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Editas Medicine's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=2.76/5.85
=0.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Editas Medicine's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Editas Medicine's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.746/134.9266*134.9266
=0.746

Current CPI (Mar. 2025) = 134.9266.

Editas Medicine Quarterly Data

Book Value per Share CPI Adj_Book
201506 0.000 100.684 0.000
201509 3.575 100.392 4.805
201512 -2.328 99.792 -3.148
201603 5.725 100.470 7.688
201606 5.296 101.688 7.027
201609 4.779 101.861 6.330
201612 3.758 101.863 4.978
201703 5.071 102.862 6.652
201706 4.522 103.349 5.904
201709 4.249 104.136 5.505
201712 4.675 104.011 6.065
201803 5.299 105.290 6.791
201806 4.885 106.317 6.200
201809 4.725 106.507 5.986
201812 4.843 105.998 6.165
201903 4.439 107.251 5.584
201906 3.921 108.070 4.895
201909 4.111 108.329 5.120
201912 4.828 108.420 6.008
202003 4.280 108.902 5.303
202006 6.872 108.767 8.525
202009 7.094 109.815 8.716
202012 6.291 109.897 7.724
202103 9.456 111.754 11.417
202106 8.999 114.631 10.592
202109 8.589 115.734 10.013
202112 8.090 117.630 9.280
202203 7.474 121.301 8.314
202206 6.773 125.017 7.310
202209 6.032 125.227 6.499
202212 5.239 125.222 5.645
202303 4.601 127.348 4.875
202306 4.900 128.729 5.136
202309 4.414 129.860 4.586
202312 4.269 129.419 4.451
202403 3.580 131.776 3.666
202406 2.815 132.554 2.865
202409 2.128 133.029 2.158
202412 1.623 133.157 1.645
202503 0.746 134.927 0.746

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Editas Medicine  (NAS:EDIT) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Editas Medicine Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Editas Medicine's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Editas Medicine Business Description

Traded in Other Exchanges
Address
11 Hurley Street, Cambridge, MA, USA, 02141
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
Executives
Linda Burkly officer: EVP, CHIEF SCIENTIFIC OFFICER 1 MAIN STREET, CAMBRIDGE MA 02142
Gilmore Neil O'neill director, officer: CEO 215 FIRST STREET, CAMBRIDGE MA 02142
Erick Lucera officer: EVP, CHIEF FINANCIAL OFFICER 138 THISTLE ROAD, NORTH ANDOVER MA 08145
Baisong Mei officer: SVP, CHIEF MEDICAL OFFICER C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142
Jessica Hopfield director C/O 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Bruce Eaton officer: EVP, Chief Business Officer C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142
Michelle Robertson officer: Chief Financial Officer C/O MOMENTA PHARMACEUTICALS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Elliott M. Levy director C/O OMEGA THERAPEUTICS, INC., 20 ACORN PARK D, CAMBRIDGE MA 02140
Mark S Shearman officer: EVP, Chief Scientific Officer C/O APPLIED GENETIC TECHNOLOGIES CORP, 11801 RESEARCH DRIVE, SUITE D, ALACHUA FL 32615
Lisa Anne Michaels officer: EVP/Chief Medical Officer C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142
Bernadette Connaughton director C/O VISTERRA, INC., ONE KENDALL SQUARE, #B3301, CAMBRIDGE MA 02139
James C Mullen director 940 WINTER STREET, PERKINELMER, INC LEGAL DEPARTMENT, WALTHAM MA 02451
Emma Reeve director C/O PAREXEL INTERNATIONAL CORPORATION, 195 WEST STREET, WALTHAM MA 02451
Cynthia Collins director 65 WEST WATKINS MILL ROAD, GAITHERSBURG MD 20878
Meeta Chatterjee director C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142